DaVita Inc. (NYSE:DVA) Given Average Recommendation of “Hold” by Brokerages

DaVita Inc. (NYSE:DVAGet Free Report) has been given an average rating of “Hold” by the eight research firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $145.60.

A number of brokerages have recently commented on DVA. Zacks Research raised DaVita from a “strong sell” rating to a “hold” rating in a research report on Friday, November 28th. Wall Street Zen downgraded shares of DaVita from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Cowen reissued a “hold” rating on shares of DaVita in a research report on Monday, November 3rd. UBS Group restated a “buy” rating on shares of DaVita in a report on Monday, December 15th. Finally, Truist Financial decreased their price objective on shares of DaVita from $140.00 to $128.00 and set a “hold” rating for the company in a research report on Monday, January 5th.

Check Out Our Latest Analysis on DaVita

DaVita Trading Down 1.0%

DaVita stock opened at $111.43 on Friday. The firm has a market capitalization of $7.87 billion, a P/E ratio of 11.48, a P/E/G ratio of 0.69 and a beta of 0.99. DaVita has a twelve month low of $108.67 and a twelve month high of $179.60. The stock’s fifty day simple moving average is $117.66 and its 200-day simple moving average is $128.98.

DaVita (NYSE:DVAGet Free Report) last released its earnings results on Wednesday, October 29th. The company reported $2.51 EPS for the quarter, missing the consensus estimate of $3.17 by ($0.66). DaVita had a negative return on equity of 13,370.89% and a net margin of 5.80%.The company had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.43 billion. During the same period in the previous year, the firm earned $2.59 earnings per share. The company’s revenue for the quarter was up 4.8% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. Sell-side analysts predict that DaVita will post 10.76 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. NewEdge Advisors LLC boosted its holdings in DaVita by 20.8% in the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after purchasing an additional 88 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of DaVita by 19.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock worth $27,403,000 after buying an additional 28,739 shares during the last quarter. Strs Ohio acquired a new position in shares of DaVita in the 1st quarter valued at $1,429,000. Sovran Advisors LLC purchased a new position in shares of DaVita in the 2nd quarter valued at $472,000. Finally, Wedge Capital Management L L P NC raised its stake in DaVita by 3.3% during the 2nd quarter. Wedge Capital Management L L P NC now owns 268,444 shares of the company’s stock worth $38,240,000 after acquiring an additional 8,538 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

About DaVita

(Get Free Report)

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.

Recommended Stories

Analyst Recommendations for DaVita (NYSE:DVA)

Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.